Agios Pharmaceuticals (AGIO) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Schrodinger (SDGR) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 35.4% versus a loss of 22.2%. Over five years, AGIO leads with a -31.3% price change compared with -50.7% for SDGR. Schrodinger is the larger company by market cap ($2.04 billion vs $1.90 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | SDGR |
|---|---|---|
| Share price | $31.79 | $27.29 |
| Market cap | $1.90B | $2.04B |
| 1-day change | +0.22% | -5.57% |
| YTD return | +16.79% | +52.63% |
| 1-year return | -22.22% | +35.37% |
| 5-year return | -31.31% | -50.70% |
| EPS (TTM) | $-7.03 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.00 | $33.78 |
| 52-week low | $22.24 | $10.95 |
| Distance from 52-week high | -30.89% | -19.21% |
| Analyst consensus | buy | none |
| Avg. price target upside | +44.70% | -21.47% |
| Average volume | 1.04M | 1.74M |
| Shares outstanding | 59.70M | 65.64M |
| Employees | 539 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed AGIO by 57.6 percentage points over the past year.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
AGIO vs SDGR FAQ
Which is bigger, Agios Pharmaceuticals or Schrodinger?
Schrodinger (SDGR) is larger, with a market capitalization of $2.04B compared with $1.90B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or SDGR?
SDGR returned +35.37% over the past 12 months, compared with -22.22% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.